| Source: |
| Type: |
| PDPK1 - 3-Phosphoinositide-Dependent Protein Kinase 1 Abbreviation: PDPK1, PDK1 Type: Serine/threonine protein kinase / PI3K pathway signaling kinase / AGC kinase activator Function: PDPK1 is a central signaling kinase downstream of phosphoinositide 3-kinase. It phosphorylates and activates multiple AGC-family kinases, including AKT, S6K, SGK, RSK, and selected PKC isoforms, thereby regulating proliferation, survival, metabolism, migration, and cellular growth. Cancer: ↑ Frequently overexpressed, hyperactivated, or functionally dysregulated in cancer. Increased PDPK1 signaling enhances PI3K-AKT pathway output, proliferation, survival, migration, invasion, metastasis, metabolic adaptation, and resistance to anticancer therapies. Genetic or pharmacological suppression of PDPK1 can inhibit tumor growth and restore treatment sensitivity in experimental models. Favorable Direction in Cancer: ↓ PDPK1 expression or kinase activity is generally favorable. |
| 2044- | PB, | DCA, | Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate |
| - | in-vivo, | NA, | NA |
| 998- | PB, | Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect |
| - | in-vivo, | NA, | NA |
| 2380- | PBG, | Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy |
| - | Review, | Var, | NA |
| 2471- | RES, | Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression |
| - | in-vivo, | Diabetic, | NA |
| 2472- | RES, | Resveratrol Restores Sirtuin 1 (SIRT1) Activity and Pyruvate Dehydrogenase Kinase 1 (PDK1) Expression after Hemorrhagic Injury in a Rat Model |
| - | in-vivo, | Nor, | NA |
| 2469- | SK, | Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2 |
| - | in-vitro, | Lung, | H1975 |
| 2470- | SK, | PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism |
| - | in-vitro, | Lung, | H1299 |
| - | vitro+vivo, | Lung, | NA |
| 2125- | TQ, | Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | RCC, | Caki-1 |
| 1067- | VitC, | Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer |
| - | in-vivo, | CRC, | NA |
| 3140- | VitC, | Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HEK293 |
| 3142- | VitC, | Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF12A |
| 2301- | Wog, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:246 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid